Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia

Summary

The purpose of this study is to determine whether tifacogin is effective and safe in the treatment of patients with severe community-acquired pneumonia.

Timeline

Start

2004-05

Primary completion

2008-07

Completion

2008-07

Outcome

Missed primary endpoint

paper Tifacogin administration did not significantly reduce mortality in any severe CAP patient. PMID 19284881 ↗

Publications

• Laterre PF, Opal SM, Abraham E, LaRosa SP, Creasey AA, Xie F, Poole L, Wunderink RG. A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia. Crit Care. 2009;13(2):R36. doi: 10.1186/cc7747. Epub 2009 Mar 15.

Drugs

Indications